The European Medicines Agency (EMA) confirmed the link between the active ingredient in Ozempic, semaglutide, and NAION (non-arteritic anterior ischemic optic neuropathy) in early June 2025. This drug regulator said further that a semaglutide NAION side effect warning would be added to the drug labels for the semaglutide-containing drugs Wegovy, … [Read more...]